QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Pregnancy and Breastfeeding Pharmacovigilance

Test your understanding of the concepts covered by GVP Product- or Population-Specific Considerations III: Pregnancy and Breastfeeding.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An external registry has enrolled many pregnancies, but exposure dates are poorly recorded and follow-up is incomplete. What should the MAH conclude about the registry?

It is adequate because enrolment numbers are high It is adequate because external providers are presumed independent Its fitness for the pharmacovigilance purpose is limited and requires quality and process evaluation It should be used as definitive evidence of no risk

Question 2 of 10 Which missing data element would be most important when investigating a suspected effect limited to organogenesis?

The patient’s preferred contact method, regardless of whether follow-up is planned The exact colour of the product packaging The timing and duration of exposure relative to gestational development The date on which the case was entered into the safety database

Question 3 of 10 What is the appropriate relationship between a pregnancy signal and general signal management?

Pregnancy signals require a completely separate scientific standard Pregnancy signals should bypass the usual signal-management framework The general signal-management framework applies, supplemented by pregnancy-specific clinical and epidemiological considerations Pregnancy signals can be assessed only through spontaneous reports

Question 4 of 10 Several congenital anomalies are reported among pregnancies exposed to a medicine. Which conclusion is scientifically most appropriate initially?

The medicine is teratogenic because the anomalies occurred after exposure The cases demonstrate a causal association if the exposure preceded the outcome The findings warrant evaluation using phenotype, exposure timing, background risk and alternative explanations The cases can be dismissed because congenital anomalies occur naturally

Question 5 of 10 A medicine is mainly prescribed to patients with severe disease, and exposed pregnancies show more preterm births than expected. What potential explanation must be considered explicitly?

Confounding by indication Reporter fatigue Therapeutic duplication Lack of product traceability

Question 6 of 10 Why should concomitant medicines and other exposures be collected in pregnancy safety reports?

They are required only to determine whether the patient followed instructions They may provide alternative explanations, interact biologically or have different relevant developmental windows Their presence automatically makes the primary product non-causal They are relevant only when the outcome is maternal

Question 7 of 10 Which statement best reflects the QPPV and MAH governance expectations described in the article?

The QPPV must personally perform every pregnancy follow-up and epidemiological analysis The MAH should have effective processes and oversight, and the QPPV should have visibility of significant concerns and process effectiveness External registry providers assume the MAH’s overall pharmacovigilance responsibility Pregnancy and breastfeeding activities do not need to be integrated with the broader pharmacovigilance system

Question 8 of 10 Which approach best preserves the distinction between maternal and child safety information in a pregnancy case?

Record all findings as one combined adverse reaction Record only the most clinically severe outcome Distinguish maternal reactions, pregnancy complications, fetal findings, neonatal outcomes and later child outcomes while linking them to the exposure Treat the child as an adverse-event reporter rather than as an exposed subject

Question 9 of 10 Which information is most useful for estimating an infant’s exposure through breast milk?

The maternal dose alone Milk concentration, estimated milk intake, dosing and feeding timing, and relevant infant characteristics The adult therapeutic range alone The duration of the mother’s illness without treatment details

Question 10 of 10 A product is detectable in breast milk, but the infant has no reported symptoms. Which interpretation is best?

Detection proves clinically important infant toxicity Detection proves that breastfeeding must stop The finding establishes presence in milk but not necessarily meaningful infant exposure or harm The finding proves that the infant received the maternal dose

Knowledge Assessment: Pregnancy and Breastfeeding Pharmacovigilance

Cookie Settings